Terms ending in 2032
Every in-force patent on Biodesix, Inc.'s record whose computed term ends in 2032, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 9,091,651 | Selected Reaction Monitoring Assays In force · High confidence | Biodesix, Inc. | In force | High confidence | |
| US 9,297,805 | Compositions, Methods and Kits for Diagnosis of Lung Cancer In force · High confidence | Biodesix, Inc. | In force | High confidence | |
| US 9,304,137 | Compositions, Methods and Kits for Diagnosis of Lung Cancer In force · High confidence | Biodesix, Inc. | In force | High confidence | |
| US 9,588,127 | Compositions, Methods and Kits for Diagnosis of Lung Cancer In force · High confidence | Biodesix, Inc. | In force | High confidence | |
| US 10,338,074 | Compositions, Methods and Kits for Diagnosis of Lung Cancer In force · High confidence | Biodesix, Inc. | In force | High confidence | |
| US 10,534,002 | Selected Reaction Monitoring Assays In force · Medium confidence | Biodesix, Inc. | In force | Medium confidence | |
| US 11,193,935 | Compositions, Methods and Kits for Diagnosis of Lung Cancer In force · Medium confidence | Biodesix, Inc. | In force | Medium confidence | |
| US 11,913,957 | Compositions, Methods and Kits for Diagnosis of Lung Cancer In force · High confidence | Biodesix, Inc. | In force | High confidence | |
| US 12,247,980 | Compositions, Methods and Kits for Diagnosis of Lung Cancer In force · High confidence | Biodesix, Inc. | In force | High confidence |
9 of 9 patents shown. Soonest term end first, then patent number.
Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.